108 related articles for article (PubMed ID: 18294809)
1. Long-term Parkinson's disease--time for optimism.
Yust-Katz S; Sthneer S; Melamed E; Djaldetti R
Biomed Pharmacother; 2008; 62(4):233-5. PubMed ID: 18294809
[TBL] [Abstract][Full Text] [Related]
2. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of early dopa treatment in Parkinson's disease.
Markham CH; Diamond SG
Ann Neurol; 1986 Apr; 19(4):365-72. PubMed ID: 3707088
[TBL] [Abstract][Full Text] [Related]
4. Levodopa induced motor complications in Thai Parkinson's disease patients.
Kulkantrakorn K; Tiamkao S; Pongchaiyakul C; Pulkes T
J Med Assoc Thai; 2006 May; 89(5):632-7. PubMed ID: 16756048
[TBL] [Abstract][Full Text] [Related]
5. [Progress in the basic and clinical aspects of Parkinson's disease].
Mizuno Y
Rinsho Shinkeigaku; 2004 Nov; 44(11):741-50. PubMed ID: 15651281
[TBL] [Abstract][Full Text] [Related]
6. Prognosis of Parkinson's disease: time to stage III, IV, V, and to motor fluctuations.
Sato K; Hatano T; Yamashiro K; Kagohashi M; Nishioka K; Izawa N; Mochizuki H; Hattori N; Mori H; Mizuno Y;
Mov Disord; 2006 Sep; 21(9):1384-95. PubMed ID: 16763980
[TBL] [Abstract][Full Text] [Related]
7. The addition of bromocriptine to long-term dopa therapy in Parkinson's disease.
Selby G
Clin Exp Neurol; 1989; 26():129-39. PubMed ID: 2701877
[TBL] [Abstract][Full Text] [Related]
8. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
Parkinson Study Group CALM Cohort Investigators
Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
[TBL] [Abstract][Full Text] [Related]
9. Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease.
Lee WY; Yoon WT; Shin HY; Jeon SH; Rhee PL
Mov Disord; 2008 Sep; 23(12):1696-700. PubMed ID: 18649391
[TBL] [Abstract][Full Text] [Related]
10. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal study of the motor response to levodopa in Parkinson's disease.
Clissold BG; McColl CD; Reardon KR; Shiff M; Kempster PA
Mov Disord; 2006 Dec; 21(12):2116-21. PubMed ID: 17029259
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of chronic levodopa therapy in Parkinson's disease.
Battistin L; Bracco F; Saladini M
J Neural Transm Suppl; 1986; 22():201-7. PubMed ID: 3465871
[TBL] [Abstract][Full Text] [Related]
13. "Panic attacks" in Parkinson's disease. A long-term complication of levodopa therapy.
Vázquez A; Jiménez-Jiménez FJ; García-Ruiz P; García-Urra D
Acta Neurol Scand; 1993 Jan; 87(1):14-8. PubMed ID: 8424307
[TBL] [Abstract][Full Text] [Related]
14. Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson's disease: involvement of L-dopa therapy.
Bouhaddi M; Vuillier F; Fortrat JO; Cappelle S; Henriet MT; Rumbach L; Regnard J
Auton Neurosci; 2004 Nov; 116(1-2):30-8. PubMed ID: 15556835
[TBL] [Abstract][Full Text] [Related]
15. [Clinical aspects and pathogenesis of the "on-off" phenomenon in Parkinson syndrome].
Jörg J; Schneider I
Fortschr Neurol Psychiatr; 1988 Jan; 56(1):22-34. PubMed ID: 3126121
[TBL] [Abstract][Full Text] [Related]
16. Levodopa in the early treatment of Parkinson's disease.
Murata M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study.
García Ruiz PJ; Sesar Ignacio A; Ares Pensado B; Castro García A; Alonso Frech F; Alvarez López M; Arbelo González J; Baiges Octavio J; Burguera Hernández JA; Calopa Garriga M; Campos Blanco D; Castaño García B; Carballo Cordero M; Chacón Peña J; Espino Ibáñez A; Gorospe Onisalde A; Giménez-Roldán S; Granés Ibáñez P; Hernández Vara J; Ibáñez Alonso R; Jiménez Jiménez FJ; Krupinski J; Kulisevsky Bojarsky J; Legarda Ramírez I; Lezcano García E; Martínez-Castrillo JC; Mateo González D; Miquel Rodríguez F; Mir P; Muñoz Fargas E; Obeso Inchausti J; Olivares Romero J; Olivé Plana J; Otermin Vallejo P; Pascual Sedano B; Pérez de Colosía Rama V; Pérez López-Fraile I; Planas Comes A; Puente Periz V; Rodríguez Oroz MC; Sevillano García D; Solís Pérez P; Suárez Muñoz J; Vaamonde Gamo J; Valero Merino C; Valldeoriola Serra F; Velázquez Pérez JM; Yáñez Baña R; Zamarbide Capdepon I
Mov Disord; 2008 Jun; 23(8):1130-6. PubMed ID: 18442107
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic factors causing hallucination in Parkinson's disease patients, especially those given selegiline.
Kamakura K; Mochizuki H; Kaida K; Hirata A; Kanzaki M; Masaki T; Nakamura R; Motoyoshi K
Parkinsonism Relat Disord; 2004 Jun; 10(4):235-42. PubMed ID: 15120098
[TBL] [Abstract][Full Text] [Related]
19. Factors that influence the occurrence of response variations in Parkinson's disease.
de Jong GJ; Meerwaldt JD; Schmitz PI
Ann Neurol; 1987 Jul; 22(1):4-7. PubMed ID: 3631919
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors of subthalamic stimulation in Parkinson's disease: a comparative study between short- and long-term effects.
Tsai ST; Lin SH; Chou YC; Pan YH; Hung HY; Li CW; Lin SZ; Chen SY
Stereotact Funct Neurosurg; 2009; 87(4):241-8. PubMed ID: 19556833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
